1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends

Charting the Biosimilar and Biobetter Development Pipeline (2013)

  • July 2013
  • 213 pages
  • Firstword Pharma
Report ID: 3509408

Summary

Table of Contents





If you need to understand the important biosimilar and biobetter drug developments worldwide then this report is critical.
The promise of biosimilars has been great but beyond the first wave of products progress has been slow. With a number of high-value biologics, particularly monoclonal antibodies such as Herceptin, Avastin, Remicade and Humira, losing patent expiry in the coming years the potential for biosimilars remains high. With greater clarity on regulatory approval and the demand of health payers for low cost medicines, the drive to develop a viable biosimilar market will continue to grow.
Who are the companies involved? What does their portfolio look like? What stage are they at? Which products offer the best potential in terms of competitor development? Critical questions needing robust answers. That is where Charting the Biosimilar and Biobetter Development Pipeline (2013) comes in.





Charting the Biosimilar and Biobetter Development Pipeline (2013) will help you to:


Understand the landscape of biosimilar/biobetter development through pipeline analysis of all known biosimilar developers worldwide
Drill down to discover the levels of potential biosimilar and biobetter competition by therapy area, drug class, development status, and country
Establish the level of biosimilar/biobetter competition to leading brands
Learn which biosimilar developers are potential future competitors or collaborators
Interrogate the development portfolio of over 300 companies and discover which are the leaders in biosimilar/biobetter development
Identify development hotspots and know where research is taking place







NEW FULLY UPDATED EDITION INCLUDES ANALYSIS AND DATAFILE

The massively expanded second edition of this leading drug intelligence report provides a complete, practical and highly-detailed insight into the status of 868 biosimilar/biobetter drugs in development from over 300 companies worldwide. Widely considered to be the most comprehensive analysis of its type, Charting the Biosimilar and Biobetter Development Pipeline (2013) is delivered in two modules:
1. Biosimilar Datafile – New this edition!
Enjoy the practical benefits of a Microsoft Excel file containing data on biosimilar and biobetter drugs currently marketed or known to be in clinical development worldwide. Each drug can be seen in the context of data on their biologic reference products and content can readily be filtered on key indicators such as:



Product Name/Development Code
Developer(s)
HQ Location
Reference Product
Originator Company
Product Type
Stage of Development (US)
Stage of Development (EU)
Therapy Area
EU Patent Expiry
US Patent Expiry
Brand Name (reference products)
Sales Value (reference products)


Using the tables provided you can effortlessly drill down into the content to identify biosimilars/biobetters in development by country, company, ATC classification, stage of development therapeutic area. Better still, the data can easily be exported to your own analytics or competitive intelligence system.


2. Biosimilar Development Analysis Report
This completely updated and expanded report volume utilises the Datafile content to produce more than 200 clear tables, charts, graphs and maps to provide “at a glance” insights into high-level trends and significant developments. Areas covered include:



Leading biosimilar companies - number of biosimilar products in portfolio
Geographic distribution of biosimilar/biobetter research
Biosimilar development pipelines by 14 compound class and therapy areas
Biosimilar development pipelines by therapy area
Biobetter developments by compound class and therapy area
Biobetters in development by 13 therapy areas






Who should read this report?

Product managers at pharma/biotech companies with original biologics:
Identify how many biosimilars versions of your products are being developed and by whom

Product managers at biosimilar developers:
Know how many biosimilars are being developed in different therapy areas or of different originator products so that you can identify opportunity gaps/areas with less competition

Heads of licensing at pharma/biotech companies: Use the database to identify biosimilars developers that may want to license in/out their products – whilst also assessing the competitive environment for any products that they may currently license.
Investment managers at venture capital firms, seed funding bodies and investment banks:
Assess the investment potential of companies and their development pipelines: the risks are high but potential reward is great for those that bring product to market.



Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Biosimilars Market Access in the U.S.

  • $ 7500
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

The route to a formal US regulatory pathway for biosimilar approval was established with the creation of the Biologics Price Competition and Innovation Act of 2010. However, it took five more years fo ...

Biosimilars Market Access in Psoriasis

  • $ 7500
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriasis market; however, these market leaders face patent expirations and consequent ...

Biosimilar Insulin Market Access

  • $ 5000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Overview Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimila ...


Download Unlimited Documents from Trusted Public Sources

Biosimilar Statistics in Europe

  • May 2017
    33 pages
  • Biosimilar  

    Therapy  

    Insulin  

  • Europe  

    World  

View report >

Biosimilar Statistics in Europe

  • May 2017
    33 pages
  • Biosimilar  

    Therapy  

    Insulin  

  • Europe  

    World  

View report >

Biosimilar Statistics in Europe

  • May 2017
    33 pages
  • Biosimilar  

    Therapy  

    Insulin  

  • Europe  

    World  

View report >

Biosimilar Industry

2 months ago

Related Market Segments :

Biosimilar

ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.